Napralief (Naproxen)

Naproxen works by non‑selectively blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish inflammation, decrease pain signaling, and reset the hypothalamic temperature set‑point, providing analgesic, anti‑inflammatory, and antipyretic effects.

The appropriate dose of Napralief is determined by the prescribing healthcare professional based on the individual’s condition, age, renal and hepatic function, and other concurrent medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Naproxen is generally classified as a category that should be avoided in the third trimester of pregnancy because of potential fetal risks. Use during early pregnancy or while breastfeeding should only occur if the prescriber judges that the benefit outweighs the potential risk to the infant.

To order Napralief, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both naproxen (Napralief) and ibuprofen belong to the NSAID class and share similar mechanisms of COX inhibition. Naproxen has a longer half‑life, often allowing twice‑daily dosing, whereas ibuprofen typically requires three‑four times daily dosing. Individual response, safety profile, and physician preference guide the choice between them.

Napralief should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Napralief is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food or milk may reduce stomach irritation. Patients should swallow the tablet whole and not crush or chew it unless directed by a healthcare professional.

Serious risks associated with Napralief include gastrointestinal ulceration or bleeding, severe skin reactions such as Stevens‑Johnson syndrome, and impaired kidney function. Patients should seek immediate medical attention if they notice black stools, persistent vomiting, rash, swelling, or sudden changes in urine output.

Napralief should be avoided in individuals with known hypersensitivity to naproxen or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, patients with severe heart failure, and anyone who has had a recent coronary artery bypass graft. It is also contraindicated in the third trimester of pregnancy.